TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7000589

Group type: EXPERIMENTAL
Intervention: Chromium-rich brewers' yeast (9 g daily for 8 weeks)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Chromium-poor torula yeast (control)
Number of subjects: 24
Study: 31252146

Group type: EXPERIMENTAL
Intervention: Ketoconazole gel-flakes (50 mg/daily for three days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gynoconazol vaginal cream (80 mg terconazole/daily for three days)
Number of subjects: 0
Study: 29246139

Group type: EXPERIMENTAL
Intervention: Educational Program (EG)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Usual care (CG)
Number of subjects: 122
Study: 27324431

Group type: EXPERIMENTAL
Intervention: Intervention group rated 'a little worse' on the Clinicians' Global Impression of Change Scale
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group rated 'unchanged' on the Clinicians' Global Impression of Change Scale
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Activities of daily living
Number of subjects: 0
Study: 25591635

Group type: EXPERIMENTAL
Intervention: Combined therapy including reflex action and tizanidine
Number of subjects: 248

Group type: COMPARATOR
Intervention: Standard methods (reflex therapy of СЕЕР and local injections of a combination of local anesthetics with small doses of steroids)
Number of subjects: 248
Study: 22456862

Group type: EXPERIMENTAL
Intervention: Energy drink containing 80 mg of caffeine plus alcohol (0.046 and 0.087% breathalyser alcohol concentration)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo drink plus alcohol (0.046 and 0.087% breathalyser alcohol concentration)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Energy drink plus alcohol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo plus alcohol
Number of subjects: 20
Study: 20380913

Group type: EXPERIMENTAL
Intervention: High dose cannabis (19 mg delta‐9‐THC)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Low dose cannabis
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Alcohol (0.4g/kg and 0.6g/kg)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo (0g/kg alcohol)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Combination of high dose cannabis and alcohol
Number of subjects: 47
Study: 18794019

Group type: EXPERIMENTAL
Intervention: Japanese-style acupuncture (n=9)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Sham acupuncture control (n=5)
Number of subjects: 18
Study: 15699056

Group type: EXPERIMENTAL
Intervention: Brief psychosocial intervention (Dutch version of W. R. Millers' Drinker's Check‐Up), n = 61
Number of subjects: 123

Group type: COMPARATOR
Intervention: Care as usual, n = 62
Number of subjects: 123
Study: 12711931

Group type: EXPERIMENTAL
Intervention: Alcohol (0.5 g/kg, 10% w/v)
Number of subjects: 13

Group type: COMPARATOR
Intervention: 4‐methylpyrazole (10‐15 mg/kg orally)
Number of subjects: 13
Study: 10575581

Group type: EXPERIMENTAL
Intervention: Day 2 embryo transfer
Number of subjects: 0

Group type: COMPARATOR
Intervention: Day 3 embryo transfer
Number of subjects: 0
Study: 8739611

Group type: EXPERIMENTAL
Intervention: Ethanol 0.55 g/kg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Ethanol 0.85 g/kg
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 9377589

Group type: EXPERIMENTAL
Intervention: Phosphatidylcholine (PCh) 25 g
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Phosphatidylcholine (PCh) 10 g
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 3469962

Group type: EXPERIMENTAL
Intervention: Inspiratory resistive training for six weeks
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo device
Number of subjects: 18
Study: 31124194

Group type: EXPERIMENTAL
Intervention: GSK2981710 (30 g/day)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 29483060

Group type: EXPERIMENTAL
Intervention: Dulaglutide 1.5 mg
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: Dulaglutide 0.75 mg
Number of subjects: 424

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 424
Study: 27383499

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (4μg/mL) with 2mL load, 1.5ml background infusion, 0.5mL single dose, 20s locking time
Number of subjects: 150

Group type: COMPARATOR
Intervention: Normal saline at 10ml/h
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (4μg/mL)
Number of subjects: 150
Study: 25610500

Group type: EXPERIMENTAL
Intervention: FLU/FOR
Number of subjects: 243

Group type: COMPARATOR
Intervention: BUD/FOR
Number of subjects: 243

Group type: COMPARATOR
Intervention: FLU
Number of subjects: 243
Study: 24681810

Group type: EXPERIMENTAL
Intervention: Quetiapine XR (400-800 mg/day)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Risperidone (4-6 mg/day)
Number of subjects: 216
Study: 21749166

Group type: EXPERIMENTAL
Intervention: DFDBA
Number of subjects: 40

Group type: COMPARATOR
Intervention: FDBA
Number of subjects: 40
Study: 19645754

Group type: EXPERIMENTAL
Intervention: Methyl mercury intake from fish consumption
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hair mercury levels
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison with survey data
Number of subjects: 0
Study: 17578722

Group type: EXPERIMENTAL
Intervention: E2 (Estrofem, Novo Nordisk, Copenhagen, Denmark) 2 mg/d given orally over 3 months
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 15176764

Group type: EXPERIMENTAL
Intervention: Cognitive Remediation Therapy (CRT) (n = 18)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control therapy (occupational therapy activities) (n = 14)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Treatment as usual (n = 19)
Number of subjects: 63

Group type: COMPARATOR
Intervention: All treatment types
Number of subjects: 63
Study: 12490825

Group type: EXPERIMENTAL
Intervention: Venlafaxine therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other antidepressants (including tricyclic antidepressants and selective serotonin reuptake inhibitors)
Number of subjects: 0
Study: 11475716

Group type: EXPERIMENTAL
Intervention: Integrated traditional Chinese and Western Medicine (TCM‐WM)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Western medicine alone (Control)
Number of subjects: 155
Study: 8944199

Group type: EXPERIMENTAL
Intervention: Single staircase procedure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adaptive probit estimation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 0
Study: 1842458

Group type: EXPERIMENTAL
Intervention: Combination of low‐molecular dextran or low‐molecular hydroxyethyl starch and hyperbaric oxygenation
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygenation (100% oxygen at 2.5 bar)
Number of subjects: 500
Study: 6889714

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide plus cisplatin (combination chemotherapy)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Cyclophosphamide (single-agent chemotherapy)
Number of subjects: 42
Study: 30887050

Group type: EXPERIMENTAL
Intervention: Terlipressin with albumin
Number of subjects: 184

Group type: COMPARATOR
Intervention: Placebo with albumin
Number of subjects: 184
Study: 30616685

Group type: EXPERIMENTAL
Intervention: Walkbot‐S™ RAGT group
Number of subjects: 44

Group type: COMPARATOR
Intervention: Treadmill training group
Number of subjects: 44
Study: 28139349

Group type: EXPERIMENTAL
Intervention: Ozanezumab (15 mg/kg)
Number of subjects: 307

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Ozanezumab
Number of subjects: 307
Study: 25613751

Group type: EXPERIMENTAL
Intervention: Enteral formula with prebiotics (lactic acid bacteria‐fermented milk products, galacto‐oligosaccharide, bifidogenic growth stimulator)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard formula without prebiotics
Number of subjects: 0
Study: 24918330

Group type: EXPERIMENTAL
Intervention: Subparaneural injection of 0.3 mL/kg mepivacaine 10 mg/mL
Number of subjects: 48

Group type: COMPARATOR
Intervention: Circumferential extraneural injection of 0.3 mL/kg mepivacaine 10 mg/mL
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Unintentional intraepineural injection
Number of subjects: 48
Study: 23087262

Group type: EXPERIMENTAL
Intervention: Nasogastric tube feeding
Number of subjects: 20

Group type: COMPARATOR
Intervention: Postpyloric tube feeding
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study: 19885874

Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy (IPT)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Treatment as usual (control)
Number of subjects: 106
Study: 18097861

Group type: EXPERIMENTAL
Intervention: House dust mite impermeable covers (HDM covers) for pillows, duvets, and mattresses
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15334437

Group type: EXPERIMENTAL
Intervention: Biofeedback-assisted cognitive-behavioral treatment (BF/CBT)
Number of subjects: 92
Study: 11322865

Group type: EXPERIMENTAL
Intervention: Conventional drugs in different combinations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New treatment approaches for refractory cGvHD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical trials for new approaches
Number of subjects: 0
Study: 9853887

Group type: EXPERIMENTAL
Intervention: Methotrexate treatment (1 mg/kg injected transvaginally or intramuscularly)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Laparoscopic salpingotomy
Number of subjects: 100
Study: 8011799

Group type: EXPERIMENTAL
Intervention: Dexamethasone (DEX) 0.5 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Dexamethasone (DEX) 0.25, 0.5, and 1.0 mg
Number of subjects: 30
Study: 1678691

Group type: EXPERIMENTAL
Intervention: Ribavirin
Number of subjects: 287

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 287
Study: 7143011

Group type: EXPERIMENTAL
Intervention: Cyproheptadine (6 mg to 24 mg per day)
Number of subjects: 6
Study: 31328281

Group type: EXPERIMENTAL
Intervention: Family-focused cognitive behavioral treatment (F-CBT)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Enhanced treatment-as-usual (E-TAU)
Number of subjects: 147
Study: 28894075

Group type: EXPERIMENTAL
Intervention: Dongchimi juice
Number of subjects: 32

Group type: COMPARATOR
Intervention: Chlorhexidine solution (0.12% dilution)
Number of subjects: 32
Study: 27471390

Group type: EXPERIMENTAL
Intervention: Programmed intermittent epidural bolus (IEB)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Continuous epidural infusion (CEI)
Number of subjects: 200
Study: 23639779

Group type: EXPERIMENTAL
Intervention: Intravenous ferric carboxymaltose (FCM)
Number of subjects: 415

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 415
Study: 20724740

Group type: EXPERIMENTAL
Intervention: Arm resistance training, 3 times a week for 6 weeks
Number of subjects: 36

Group type: COMPARATOR
Intervention: Sham control, 3 times a week for 6 weeks
Number of subjects: 36
Study: 19735563

Group type: EXPERIMENTAL
Intervention: Physical Therapy exclusively with standardized protocols
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Shoulder Dynasplint system exclusively
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Combined treatment with Shoulder Dynasplint and standardized Physical Therapy
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (Group I)
Number of subjects: 62
Study: 17283299

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention including office-based expert system assessment, brief stage-based counseling, expert system-generated feedback reports, printed manual, and mailed tip sheets.
Number of subjects: 819

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention as described above.
Number of subjects: 819

Group type: COMPARATOR
Intervention: Control group received a physical activity and nutrition intervention.
Number of subjects: 819

Group type: EXPERIMENTAL
Intervention: Completion of more intervention sessions.
Number of subjects: 819
Study: 15209578

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 1000 mg PO 1 hour before cath/PCI and 4 hours later
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 80
Study: 11755455

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 300 microg of CNP
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 9520616

Group type: EXPERIMENTAL
Intervention: Methimazole treatment for 11.2 ± 1.0 weeks
Number of subjects: 12
Study: 7975860

Group type: EXPERIMENTAL
Intervention: Plasma-derived vaccine (Hevac B)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Recombinant HBsAg vaccine (Engerix-B)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both vaccines
Number of subjects: 50
Study: 3132383

Group type: EXPERIMENTAL
Intervention: roxithromycin (150 mg 2 X day)
Number of subjects: 160

Group type: COMPARATOR
Intervention: cephradine (1.0 g 2 X day)
Number of subjects: 160
Study: 31924662

Group type: EXPERIMENTAL
Intervention: BLT+MLT+MP
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: BLT+placebo of MLT+placebo of MP
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: BLT
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: MLT
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: MP
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control (placebo for BLT, MLT and MP)
Number of subjects: 67
Study: 31230261

Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg/day
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Tadalafil 5 mg/day
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Tadalafil 5 mg + Aspirin 100 mg
Number of subjects: 336

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 336
Study: 28463849

Group type: EXPERIMENTAL
Intervention: Febuxostat (40 mg thrice weekly)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 25416737

Group type: EXPERIMENTAL
Intervention: Mirror therapy-based action observation (AO) group
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control observation (CO) group
Number of subjects: 37

Group type: COMPARATOR
Intervention: Comparison between AO and CO groups
Number of subjects: 37
Study: 23353589

Group type: EXPERIMENTAL
Intervention: Spinal anesthesia followed by intravenous morphine analgesia (Group A)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Epidural anesthesia followed by epidural analgesia (Group B)
Number of subjects: 56
Study: 21533031

Group type: EXPERIMENTAL
Intervention: Fixed-dose combination ART
Number of subjects: 96
Study: 18280129

Group type: EXPERIMENTAL
Intervention: Stair-climbing
Number of subjects: 16

Group type: COMPARATOR
Intervention: Walking
Number of subjects: 16
Study: 16483745

Group type: EXPERIMENTAL
Intervention: Aripiprazole (initiated at 15 mg/d, adjusted between 10-30 mg/d)
Number of subjects: 1599

Group type: COMPARATOR
Intervention: Safety Control (another antipsychotic medication, dosed according to prescribing guidelines)
Number of subjects: 1599
Study: 14512669

Group type: EXPERIMENTAL
Intervention: Proportional Assist Ventilation (PAV)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Pressure Support Ventilation (PSV)
Number of subjects: 9
Study: 10856385

Group type: EXPERIMENTAL
Intervention: bFGF (basic fibroblast growth factor) 30 to 100 microg/kg
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: bFGF (basic fibroblast growth factor) 3 to 30 microg/kg
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 9165611

Group type: EXPERIMENTAL
Intervention: Alarm plus 40 micrograms desmopressin (Minirin, DDAVP) nasal spray
Number of subjects: 71

Group type: COMPARATOR
Intervention: Alarm monotherapy
Number of subjects: 71
Study: 1489500

Group type: EXPERIMENTAL
Intervention: Porcine collagen membrane dressing
Number of subjects: 2

Group type: COMPARATOR
Intervention: Petroleum jelly gauze dressing
Number of subjects: 2
Study: 4085353

Group type: EXPERIMENTAL
Intervention: Activated charcoal
Number of subjects: 7

Group type: COMPARATOR
Intervention: Water alone
Number of subjects: 7
Study: 29767638

Group type: EXPERIMENTAL
Intervention: TDF/FTC (Tenofovir Disoproxil Fumarate/Emtricitabine)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 27163250

Group type: EXPERIMENTAL
Intervention: Mobile upper extremity rehabilitation program (MoU-Rehab) combined with conventional occupational therapy (OT)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional occupational therapy (OT) alone
Number of subjects: 24
Study: 25339206

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (AET)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 57
Study: 22815078

Group type: EXPERIMENTAL
Intervention: STAM‐Dem protocol (2 weekly sessions of 45 minutes for 12 weeks)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 51
Study: 20133918

Group type: EXPERIMENTAL
Intervention: 0.9 mg/kg IV tissue plasminogen activator within 3 hours of symptom onset
Number of subjects: 113
Study: 17853158

Group type: EXPERIMENTAL
Intervention: 200 microg sublingual misoprostol 2 hours prior to the procedure
Number of subjects: 72

Group type: COMPARATOR
Intervention: 400 microg vaginal misoprostol 3 hours prior to the procedure
Number of subjects: 72
Study: 16225494

Group type: EXPERIMENTAL
Intervention: Ghrelin 40 microg/30 min
Number of subjects: 6
Study: 12160332

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil (CMF)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo infusion (saline)
Number of subjects: 30
Study: 10480442

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 0
Study: 8647514

Group type: EXPERIMENTAL
Intervention: Patients with newly diagnosed chronic lymphoid malignancies
Number of subjects: 59

Group type: COMPARATOR
Intervention: Patients with localized disease
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: High-grade non-Hodgkin's lymphoma
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Selenium levels
Number of subjects: 59
Study: 2282940

Group type: EXPERIMENTAL
Intervention: Krypton laser treatment
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Argon laser treatment
Number of subjects: 91
Study: 7308950

Group type: EXPERIMENTAL
Intervention: Unclamped umbilical cord
Number of subjects: 414

Group type: COMPARATOR
Intervention: Clamped umbilical cord
Number of subjects: 414
Study: 31227019

Group type: EXPERIMENTAL
Intervention: Misoprostol (400 μg administered sublingually every 3 hours up to five doses within 24 hours)
Number of subjects: 1192

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 1192
Study: 28513179

Group type: EXPERIMENTAL
Intervention: Watermelon juice enriched with l-Citrulline and pomegranate ellagitannins
Number of subjects: 19
Study: 25655899

Group type: EXPERIMENTAL
Intervention: Regorafenib 160 mg once daily
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Regorafenib
Number of subjects: 17
Study: 24101149

Group type: EXPERIMENTAL
Intervention: Oral anticoagulation (OAC) discontinued after successful AF ablation; average 7.3 months follow-up off OAC.
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Patients remaining on OAC post-ablation; 32/37 (86.5%) of patients with AF post-ablation remained on OAC.
Number of subjects: 108

Group type: COMPARATOR
Intervention: Patients off OAC; 0% bleeding risk reported.
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Patients AF free post-ablation; 71 patients (65.7%) were AF free 2.8 years after last ablation.
Number of subjects: 108
Study: 21854674

Group type: EXPERIMENTAL
Intervention: Rapid Rhino
Number of subjects: 30

Group type: COMPARATOR
Intervention: Merocel
Number of subjects: 30
Study: 18583993

Group type: EXPERIMENTAL
Intervention: Cooled BSS Plus at 10 degrees C
Number of subjects: 70

Group type: COMPARATOR
Intervention: Room temperature BSS Plus at 23 degrees C
Number of subjects: 70
Study: 17668977

Group type: EXPERIMENTAL
Intervention: MM + SRP
Number of subjects: 127

Group type: COMPARATOR
Intervention: SRP alone
Number of subjects: 127
Study: 15350316

Group type: EXPERIMENTAL
Intervention: Screening examination including IOP measurement, CCT, slit-lamp examination, fundus photography, and visual field test.
Number of subjects: 3021

Group type: EXPERIMENTAL
Intervention: POAG with IOP levels of 21 mmHg or less.
Number of subjects: 3021

Group type: EXPERIMENTAL
Intervention: POAG with IOP levels of more than 21 mmHg.
Number of subjects: 3021

Group type: EXPERIMENTAL
Intervention: Average IOP for eyes with POAG (right eye).
Number of subjects: 3021

Group type: EXPERIMENTAL
Intervention: Average IOP for eyes with POAG (left eye).
Number of subjects: 3021

Group type: EXPERIMENTAL
Intervention: Mean CCT of POAG eyes with IOP levels of 21 mmHg or less (right eye).
Number of subjects: 3021

Group type: EXPERIMENTAL
Intervention: Mean CCT of POAG eyes with IOP levels of 21 mmHg or less (left eye).
Number of subjects: 3021
Study: 12217084

Group type: EXPERIMENTAL
Intervention: T(LBE)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: T(UBE)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: T(UBE) and T(LBE)
Number of subjects: 12
Study: 9624641

Group type: EXPERIMENTAL
Intervention: High Glycemic Index (HGI)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Low Glycemic Index (LGI)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (CON)
Number of subjects: 8
Study: 7660345

Group type: EXPERIMENTAL
Intervention: Adult bronchoscope
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Paediatric bronchoscope
Number of subjects: 20
Study: 2651016

Group type: EXPERIMENTAL
Intervention: Tizanidine (max. 20 mg/day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Baclofen (max. 50 mg/day)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Tizanidine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Baclofen
Number of subjects: 30
Study: 340132

Group type: EXPERIMENTAL
Intervention: Tinidazole (2 g once daily for 3 days)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Metronidazole (2 g once daily for 3 days)
Number of subjects: 56
Study: 31941864

Group type: EXPERIMENTAL
Intervention: Blueberry leaves (BL) beverage
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 0